Karyopharm Therapeutics Inc.KPTINASDAQ

Revenue (LTM)

$146M

+0.6% YoY

Net Income (LTM)

$-196M

-156.5% YoY

Free Cash Flow

$-75M

Revenue CAGR (5Y)

+6.2%

—Marginsstable

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	210	157↓25.1%	146↓7.0%	145↓0.5%	146↑0.6%
Gross Profit	206	152↓26.4%	141↓7.1%	139↓1.3%	140↑0.6%
Operating Income	-98	-142↓44.7%	-130↑8.9%	-119↑7.8%	-91↑24.1%
Net Income	-124	-165↓33.2%	-143↑13.4%	-76↑46.6%	-196↓156.5%
EBITDA	-97	-139↓43.6%	-118↑15.0%	-39↑67.4%	-90↓134.2%
EPS Diluted	-24.75	-30.28↓22.3%	-18.79↑37.9%	-9.41↑49.9%	-17.93↓90.5%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	190	135↓29.0%	52↓61.4%	62↑19.6%	61↓3.1%
Total Current Assets	276	350↑27.1%	234↓33.2%	156↓33.1%	103↓34.1%
Total Assets	305	358↑17.3%	240↓32.9%	164↓31.6%	108↓34.1%
Total Current Liabilities	74	66↓10.6%	69↑5.4%	92↑32.8%	92↓0.2%
Total Liabilities	385	375↓2.6%	377↑0.5%	350↓7.0%	401↑14.5%
Total Equity	-80	-17↑79.1%	-136↓717.8%	-186↓36.6%	-293↓57.5%
Total Debt	181	179↓0.8%	177↓1.1%	195↑9.9%	234↑20.1%
Net Debt	-10	44↑544.1%	125↑184.3%	132↑5.8%	173↑31.1%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-107	-150↓39.6%	-93↑38.0%	-127↓37.5%	-75↑40.9%
Capital Expenditure	-6	-0↑97.9%	0	-0	0
Free Cash Flow	-113	-150↓32.7%	-93↑38.0%	-128↓37.6%	-75↑40.9%
Stock-Based Comp	30	35↑18.9%	22↓38.7%	18↓15.1%	14↓23.7%
Net Change in Cash	108	-61↓155.9%	-84↓38.2%	10↑111.5%	-2↓120.0%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance